FDA Sends Interleukin Genetics, DNA-CardioCheck Untitled Letters | GenomeWeb

This article as been updated to note three different tests cited in the FDA's letter and to correctly state that Interleukin's deal with NYU focuses on advancing a test for osteoarthritis progression, not PerioPredict.

NEW YORK (GenomeWeb) – The US Food and Drug Administration has issued untitled letters to Interleukin Genetics and DNA-CardioCheck, requesting additional information on their direct-to-consumer tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.